Dapagliflozin and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial

被引：0
|
作者：
Ostrominski, John [1 ]
Vaduganathan, M. [1 ]
Selvaraj, S. [2 ]
Claggett, B. [1 ]
Desai, A. [1 ]
Jhund, P. [3 ]
Kosiborod, M. [4 ]
Lam, C. [5 ]
Inzucchi, S. [6 ]
Martinez, F. [7 ]
De Boer, R. [8 ]
Hernandez, A. [9 ]
Shah, S. [10 ]
Mcmurray, J. [3 ]
Solomon, S. [1 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Duke Univ, Med Ctr, Durham, NC 27706 USA
[3] Univ Glasgow, Glasgow, Lanark, Scotland
[4] St Lukes Mid Amer Heart Inst, Kansas City, MO USA
[5] Natl Heart Ctr Singapore, Singapore, Singapore
[6] Yale Sch Med, New Haven, CT USA
[7] Univ Nacl Cordoba, Cordoba, Argentina
[8] Univ Med Ctr Groningen, Groningen, Netherlands
[9] Duke Clin Res Inst, Durham, NC USA
[10] Northwestern Mem Hosp, Chicago, IL 60611 USA
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2023年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：41 / 41
页数：1
相关论文
共 50 条
  • [21] Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction
    Cunningham, Jonathan W.
    Vaduganathan, Muthiah
    Claggett, Brian L.
    Kulac, Ian J.
    Desai, Akshay S.
    Jhund, Pardeep S.
    de Boer, Rudolf A.
    DeMets, David
    Hernandez, Adrian F.
    Inzucchi, Silvio E.
    Kosiborod, Mikhail N.
    Lam, Carolyn S. P.
    Martinez, Felipe
    Shah, Sanjiv J.
    McGrath, Martina M.
    O'Meara, Eileen
    Wilderang, Ulrica
    Lindholm, Daniel
    Petersson, Magnus
    Langkilde, Anna Maria
    McMurray, John J., V
    Solomon, Scott D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 80 (14) : 1302 - 1310
  • [22] The Effects of Dapagliflozin on Symptoms, Function and Quality of Life in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: Results From the DELIVER Trial
    Kosiborod, Mikhail N.
    Bhatt, Ankeet
    Claggett, Brian
    Vaduganathan, Muthiah
    Kulac, Ian
    Lam, Carolyn S.
    Hernandez, Adrian F.
    Martinez, Felipe
    Inzucchi, Silvio E.
    Shah, Sanjiv J.
    De Boer, Rudolf A.
    Jhund, Pardeep S.
    Desai, Akshay S.
    Fang, James C.
    Han Yaling
    Comin-Colet, Josep
    Vardeny, Orly
    Lind-Holm, Daniel
    Wilderang, Ulrica
    Bengtsson, Olof
    McMurray, John J.
    Solomon, Scott
    CIRCULATION, 2022, 146 (25) : E596 - E597
  • [23] The cost-effectiveness of dapagliflozin in heart failure with preserved or mildly reduced ejection fraction: a European health-economic analysis of the DELIVER trial
    Booth, David
    Davis, Jason A.
    McEwan, Phil
    Solomon, Scott D.
    McMurray, John J. V.
    De Boer, Rudolf A.
    Comin-Colet, Josep
    Bachus, Erasmus
    Chen, Jieling
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (08) : 1386 - 1395
  • [24] Effect of dapagliflozin on individual components of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
    Peikert, A.
    Chandra, A.
    Vaduganathan, M.
    Kosiborod, M. N.
    Claggett, B. L.
    Desai, A. S.
    Jhund, P. S.
    Lam, C. S. P.
    Inzucchi, S. E.
    Martinez, F. A.
    De Boer, R. A.
    Hernandez, A. F.
    Shah, S. J.
    Mcmurray, J. J. V.
    Solomon, S. D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 172 - 172
  • [25] Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction
    Talha, Khawaja M.
    Butler, Javed
    CLINICAL CARDIOLOGY, 2022, 45 : S31 - S39
  • [26] Dapagliflozin: a potential lifesaver for "heart failure patients with mildly reduced or preserved ejection fraction" in the world
    Bijarani, Faizan Shafqat Ali
    Nazeer, Ahsan
    Shaikh, Bisma
    JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION, 2023, 73 (12) : 2529 - 2529
  • [27] DAPAGLIFLOZIN VERSUS SACUBITRIL-VALSARTAN FOR HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION
    Arbel, Ronen
    Oberoi, Mansi
    Alnsasra, Hilmi
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 628 - 628
  • [28] Dapagliflozin versus sacubitril-valsartan for heart failure with mildly reduced or preserved ejection fraction
    Arbel, Ronen
    Azab, Abed N.
    Oberoi, Mansi
    Aboalhasan, Enis
    Star, Artyom
    Elhaj, Khaled
    Khalil, Fouad
    Alnsasra, Hilmi
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [29] Renal and blood pressure effects of dapagliflozin in recently hospitalized patients with heart failure with mildly reduced or preserved ejection fraction: Insights from the DELIVER trial
    Chatur, Safia
    Cunningham, Jonathan W.
    Vaduganathan, Muthiah
    Mc Causland, Finnian R.
    Claggett, Brian L.
    Desai, Akshay S.
    Miao, Zi Michael
    Jhund, Pardeep S.
    de Boer, Rudolf A.
    Hernandez, Adrian F.
    Inzucchi, Silvio E.
    Kosiborod, Mikhail N.
    Lam, Carolyn S. P.
    Martinez, Felipe A.
    Shah, Sanjiv J.
    Petersson, Magnus
    Langkilde, Anna Maria
    McMurray, John J. V.
    Solomon, Scott D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 (07) : 1170 - 1175
  • [30] Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial
    Vaduganathan, Muthiah
    Claggett, Brian L.
    Jhund, Pardeep
    de Boer, Rudolf A.
    Hernandez, Adrian F.
    Inzucchi, Silvio E.
    Kosiborod, Mikhail N.
    Lam, Carolyn S. P.
    Martinez, Felipe
    Shah, Sanjiv J.
    Desai, Akshay S.
    Hegde, Sheila M.
    Lindholm, Daniel
    Petersson, Magnus
    Langkilde, Anna Maria
    McMurray, John J., V
    Solomon, Scott D.
    JAMA CARDIOLOGY, 2022, 7 (12) : 1259 - 1263
12345